Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Dimension Therapeutics, Inc. (DMTX)
|
Add to portfolio |
|
|
|
| Price: |
$5.95
| | Metrics |
| OS: |
25.4
|
M
| |
-274
|
% ROE
|
| Market cap: |
$151
|
M
| |
-320
|
% ROIC
|
|
Net cash:
|
$28.5
|
M
| |
$1.12
|
per share
|
|
EV:
|
$122
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($52.9)
|
M
| |
|
|
|
EBIT
|
($55.1)
|
M
| |
|
|
| EPS |
($2.23)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Jun-20-13 |
| Revenues | 11.5 | 7.8 | 2.8 | 2.8 |
| Revenue growth | 48.0% | 181.8% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 3.2 |
| Gross profit | 11.5 | 7.8 | 2.8 | -0.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | -13.0% |
| Research and development | 47.7 | 34.0 | 13.0 | |
| General and administrative | 12.8 | 8.7 | 2.7 | 0.4 |
| EBIT | -49.1 | -35.0 | -13.0 | -3.2 |
| EBIT margin | -427.6% | -451.2% | -470.9% | -113.0% |
| Pre-tax income | -49.0 | -35.1 | -13.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | |
| Net income | -49.0 | -35.1 | -13.0 | -3.2 |
| Net margin | -427.2% | -452.6% | -474.1% | -113.3% |
| |
| Diluted EPS | ($1.97) | ($4.41) | ($3.61) | ($2.71) |
| Shares outstanding (diluted) | 24.9 | 7.9 | 3.6 | 1.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|